Adaptimmune surges after FDA lifts partial hold; Anthera tanks on PhIII flop; Kadmon axes staffers in restructuring
Adaptimmune stock $ADAP surged 14% after the company revealed in its Q3 update that the FDA had lifted its partial hold on its lead program. When it was first announced in August, the UK biotech hurried to explain that the FDA was looking for a few answers to questions posed by regulators ahead of the launch of the registration trial.
Shares of Anthera $ANTH were battered early Thursday morning when the small biotech announced that its Phase III lupus study of blisibimod flopped, with 47% of the patients hitting the primary endpoint alongside 42% of the placebo arm. Its shares cratered, plunging 39%.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.